The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| CNTB | +22.22% | N/A | N/A | -92% |
| S&P | +18.13% | +110.72% | +16.08% | +76% |
Connect Biopharma Holdings Ltd. engages in the development of therapies for the treatment of T cell-driven inflammatory diseases. Its lead product candidate, CBP-201, is an antibody designed to target interleukin-4 receptor alpha, or IL-4Ra, which is a validated target for the treatment of inflammatory diseases such as atopic dermatitis and asthma. The company was founded by Zheng Wei and Wu Bin Pan on November 23, 2015 and is headquartered in Taicang, China.
| Q2 2025 | YOY Change | |
|---|---|---|
| Revenue | $0.05M | 0.0% |
| Gross Profit | -$0.17M | 0.0% |
| Market Cap | $54.25M | 0.0% |
| Net Income | -$12.90M | 0.0% |
| EBITDA | -$13.25M | 0.0% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q2 2025 | YOY Change | |
|---|---|---|
| Net Cash | $40.63M | 0.0% |
| Accounts Receivable | $0.00M | 0.0% |
| Inventory | 0 | 0.0% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $0.52M | 0.0% |
| Short Term Debt | $0.35M | 0.0% |
| Current | YOY Change | |
|---|---|---|
| Return On Invested Capital | -59.57% | 0.0% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$12.96M | 0.0% |
| Operating Free Cash Flow | -$12.66M | 0.0% |
| Metric | Q1 2025 | Q2 2025 | YoY Change |
|---|---|---|---|
| Price to Book | 0.33 | 0.65 | - |
| Price to Tangible Book Value | 0.33 | 0.65 | - |
| Enterprise Value to EBITDA | 4.67 | 1.25 | - |
| Total Debt | $0.94M | $0.87M | - |
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
